Lastly, the indirect control of NEAT1/KRAS was confirmed with small interfering RNA and antisense oligonucleotides both in vitro and in vivo, providing novel insight into the lncRNA‐based oncological therapeutic approach to treat human colorectal cancer. The gene discussed is KRAS; the disease is colorectal cancer.